Zurich, 30.11.2020 – An antibiotic developed in collaboration with the EU project ENABLE (European Gram Negative Anti-Bacterial Engine) is showing positive results in Phase 1, consortium member Juvabis announced.
The Swiss biotech company is part of the ENABLE consortium, as is BIOCOM AG, which is responsible for the communication and dissemination of the project progress. Juvabis announced promising results from the completion of the first human phase 1 study with its antibiotic candidate EBL-1003. A phase 1 study with a single intravenous dose in healthy volunteers showed that EBL-1003 (Apramycin) was safe and well tolerated in all dose groups. The results support further clinical development of EBL-1003 in patients.
EBL-1003 has been developed in partnership with the European Gram Negative Anti-Bacterial Engine (ENABLE), a project funded by the Innovative Medicines Initiative (IMI) for the research and development of new antibiotics and for the fight against infections specifically with multi-resistant Gram-negative pathogens. With its expertise in communication tasks for the life science sector, BIOCOM gained its place in the ENABLE consortium in 2014 and is responsible for the work package for communication and dissemination of scientific achievements.
More than 50 European partners from science and industry have joined forces in the ENABLE project over a project period of six years (project end 2021). ENABLE, which is part of the ND4BB program, has quickly developed into a bottom-up engine of drug development. ENABLE is funded by a financial contribution from the Seventh Framework Programme of the European Union (FP7/2007-2013) and the contribution in kind from EFPIA companies. It is also financially supported by contributions from academic and SME partners.